Europe and the UK are overhauling healthcare AI oversight, shifting from static approvals to continuous lifecycle monitoring to ease compliance burdens under the EU AI Act and Medical Device Regulations. Concurrently, AI captured 48% of European health venture capital in 2026, driving major funding rounds and acquisitions like GE HealthCare's $945 million deal for SOFIE Biosciences. Meanwhile, cross-border clinical pilots, sovereign compute initiatives, and digital twins are

The European healthtech and life sciences ecosystem is undergoing a decisive shift from speculative innovation to pragmatic, infrastructure-grade implementation. Capital deployment increasingly mirrors this maturation; venture funding is bypassing consumer wellness to heavily back operational “clinical plumbing,” computational biology and specialised diagnostic deep tech.

The landscape of artificial intelligence underwent a fundamental phase shift between 2025 and 2026, a period defined by the emergence of "efficiency-first" architectures that challenged the long-standing dominance of capital-intensive scaling laws. At the centre of this transformation was DeepSeek, a Chinese organisation that transitioned from a specialised quantitative research offshoot into a primary driver of global AI economics and clinical innovation. This report examine